Radioactive Iodine Most Effective Treatment for Hyperthyroidism
By MedImaging International staff writers Posted on 12 Feb 2020 |
New guidelines issued in the UK for the treatment of hyperthyroidism, including Graves' disease, place heavier emphasis on the use of radioactive iodine as the frontline treatment for patients unlikely to remain remission-free on medication.
The guideline summary, compiled by researchers from the Royal College of Physicians (London, UK), the University of Birmingham (UB; United Kingdom), and the Royal College of Obstetricians and Gynaecologists (London, UK), are part of broader guidelines on thyroid disease issued by the UK National Institute for Health and Care Excellence ((NICE; London, United Kingdom), which concludes that radioactive iodine results in cure in as many as 90% of hyperthyroidism cases.
The new NICE guidelines cite five randomized controlled trials of people with hyperthyroid disease, which collectively indicate that long-term outcomes were improved with radioactive iodine treatment compared with antithyroid drugs, despite the former having a higher risk of thyroid eye disease (also known as Graves' ophthalmopathy). In addition, eight nonrandomized studies show no evidence of a clinically important increase in cancer diagnoses or deaths between those treated with radioactive iodine and healthy controls. The guideline was published on January 29, 2020, in BMJ.
“The strongest arguments in favor of radioactive iodine as a first-line therapy were the likelihood of inducing remission of Graves' disease with radioactive iodine, the finding that radioiodine is a safe treatment, and the reduction in the need for patients to remain on antithyroid drugs, which may have significant side effects,” said senior author Kristien Boelaert, MD, PhD, of UB. “We are very pleased to have been able to work with NICE to provide clear new guidance which we hope will improve outcomes for patients with this condition.”
Most cases of hyperthyroidism are due to Graves’ disease, an autoimmune disease of the thyroid, an endocrine gland in the neck that produces two hormones secreted into the bloodstream, thyroxine (T4) and triiodothyronine (T3); T4 is converted to T3 in cells and tissues. The hormones regulate metabolism. Thyroid disorders include hypothyroidism, hyperthyroidism, nodules, cancer, Graves’ disease, and post-partum thyroiditis. The prevalence of hyperthyroidism is about 1.2% (0.5% overt and 0.7% subclinical).
Related Links:
Royal College of Physicians
University of Birmingham
Royal College of Obstetricians and Gynaecologists
UK National Institute for Health and Care Excellence
The guideline summary, compiled by researchers from the Royal College of Physicians (London, UK), the University of Birmingham (UB; United Kingdom), and the Royal College of Obstetricians and Gynaecologists (London, UK), are part of broader guidelines on thyroid disease issued by the UK National Institute for Health and Care Excellence ((NICE; London, United Kingdom), which concludes that radioactive iodine results in cure in as many as 90% of hyperthyroidism cases.
The new NICE guidelines cite five randomized controlled trials of people with hyperthyroid disease, which collectively indicate that long-term outcomes were improved with radioactive iodine treatment compared with antithyroid drugs, despite the former having a higher risk of thyroid eye disease (also known as Graves' ophthalmopathy). In addition, eight nonrandomized studies show no evidence of a clinically important increase in cancer diagnoses or deaths between those treated with radioactive iodine and healthy controls. The guideline was published on January 29, 2020, in BMJ.
“The strongest arguments in favor of radioactive iodine as a first-line therapy were the likelihood of inducing remission of Graves' disease with radioactive iodine, the finding that radioiodine is a safe treatment, and the reduction in the need for patients to remain on antithyroid drugs, which may have significant side effects,” said senior author Kristien Boelaert, MD, PhD, of UB. “We are very pleased to have been able to work with NICE to provide clear new guidance which we hope will improve outcomes for patients with this condition.”
Most cases of hyperthyroidism are due to Graves’ disease, an autoimmune disease of the thyroid, an endocrine gland in the neck that produces two hormones secreted into the bloodstream, thyroxine (T4) and triiodothyronine (T3); T4 is converted to T3 in cells and tissues. The hormones regulate metabolism. Thyroid disorders include hypothyroidism, hyperthyroidism, nodules, cancer, Graves’ disease, and post-partum thyroiditis. The prevalence of hyperthyroidism is about 1.2% (0.5% overt and 0.7% subclinical).
Related Links:
Royal College of Physicians
University of Birmingham
Royal College of Obstetricians and Gynaecologists
UK National Institute for Health and Care Excellence
Latest Nuclear Medicine News
- New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment
- Low-Dose Radiation Therapy Demonstrates Potential for Treatment of Heart Failure
- New PET Radiotracer Aids Early, Noninvasive Detection of Inflammatory Bowel Disease